MAPT and Alzheimer disease: This extends previous work in typical AD showing that decreases in SV2A on PET are associated with both Aβ (9,10) and tau PET increases (9,11,15,17) and that longitudinal reductions in SV2A PET follow a Braak staging scheme similar to that for tau PET (13).